公开(公告)号：US4958008A

公开(公告)日：1990-09-18

申请号：US216407

申请日：1988-07-07

申请人： Herve Petite ,  Philippe Menasche ,  Alain Huc

发明人： Herve Petite ,  Philippe Menasche ,  Alain Huc

IPC分类号： A61F2/00 ,  A61L27/24 ,  A61L27/36 ,  C08H1/06

CPC分类号： A61L27/3687 ,  A61L27/24 ,  C08H1/06 ,  A61F2310/00365 ,  Y10S128/08

摘要： This process, which essentially comprises the following steps:esterification of the free acid groups of the collagen,transformation of the esterified groups into hydrazides groups,transformation of the hydrazide groups into azide groups by the action of nitrous acid, is characterized in that each step is separated by a rinsing in an aqueous salt solution, and in that the step of transformation of esterified groups into azide groups and the step of transformation of hydrazide groups into azide groups by the action of nitrous acid, are performed in the presence of salt.

摘要翻译： 该方法基本上包括以下步骤：胶原的游离酸基团的酯化，酯化基团转化为酰肼基团，通过亚硝酸的作用将酰肼基转变成叠氮基团，其特征在于每个步骤 通过在盐水溶液中冲洗分离，并且在酯盐存在下进行酯化基团转化为叠氮化物基团的步骤和通过亚硝酸的作用将酰肼基团转化为叠氮基团的步骤。

公开(公告)号：US20240316061A1

公开(公告)日：2024-09-26

申请号：US18691769

申请日：2022-09-16

申请人： INSTITUT CURIE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Raphaël MARGUERON ,  Ming-Kang LEE

IPC分类号： A61K31/551 ,  A61K31/501 ,  A61P35/00

CPC分类号： A61K31/551 ,  A61K31/501 ,  A61P35/00

摘要： Methods and pharmaceutical compositions for the treatment of BAP1 deficient cancer are based on investigation of the role of BET (Bromodomain and Extra-Terminal motif proteins) in BAP1 deficient cancer and screened isogenic cells (BAP1 WT vs KO). BET inhibitors show more anti-proliferative activity against cells KO for BAP1. Using isogenic cell lines and uveal melanoma PDX derived cell lines with different status of expression for BAP1 showed a highest dose response to a BET inhibitors (OTX015 and BI894999) in BAP1 KO isogenic cells compared to WT cells and an enhanced dose response to OTX015 in a BAP1 mutated uveal melanoma (UM) derived cells compared to UM cells expressing BAP1. BET inhibitors have a role in BAP1 deficient cancer, and BET inhibitors are useful in the treatment of BAP1 deficient cancer, particularly BAP1 deficient Uveal Melanoma, clear cell Renal Carcinoma, cholangiocarcinoma and mesothelioma.

公开(公告)号：US20240243218A1

公开(公告)日：2024-07-18

申请号：US18562207

申请日：2022-05-18

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE GRENOBLE ALPES ,  INSTITUT POLYTECHNIQUE DE GRENOBLE ,  UNIVERSITE PAUL SABATIER TOULOUSE III ,  INSTITUT NATIONAL POLYTECHNIQUE DE TOULOUSE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Julien PERNOT ,  Cedric MASANTE ,  Nicolas ROUGER ,  Martin KAH ,  Clement HEBERT

IPC分类号： H01L33/00 ,  H01L33/34

CPC分类号： H01L33/0041 ,  H01L33/343

摘要： A device including a first portion, a second portion, a first contact and a second contact, the first portion being made of a semiconductor having a first doping, the second portion being made of a semiconductor having a second doping different than the first, the first portion and the second portion forming a p/n junction including a depletion zone in the first portion, the contacts being configured so that when an electric voltage (V1) is applied between the contacts, a dimension of the depletion zone depends on a value of the electric voltage, an ionization energy being defined for dopants of the second portion. The device includes an emitter generating a radiation having an energy greater than the ionization energy and illuminating the second portion with the radiation.

公开(公告)号：US20240201185A1

公开(公告)日：2024-06-20

申请号：US18556496

申请日：2022-04-21

申请人： SORBONNE UNIVERSITE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE – HOPITAUX DE PARIS

发明人： Cindy MARQUES ,  Paul REGNIER ,  David SAADOUN

IPC分类号： G01N33/564 ,  G01N33/569 ,  G01N33/574

CPC分类号： G01N33/564 ,  G01N33/56972 ,  G01N33/57407 ,  G01N2333/70553 ,  G01N2333/70578 ,  G01N2333/70596 ,  G01N2333/7158 ,  G01N2800/101

摘要： The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.

公开(公告)号：US20240139249A1

公开(公告)日：2024-05-02

申请号：US18483323

申请日：2023-10-09

申请人： ETABLISSEMENT FRANCAIS DU SANG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON ,  UNIVERSITE DE FRANCHE COMTE

发明人： Christophe FERRAND ,  Marina DESCHAMPS ,  Fabrice LAROSA

IPC分类号： A61K35/17 ,  A61P35/02 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C12N5/10 ,  C12N15/85

CPC分类号： A61K35/17 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/7155 ,  C07K16/2866 ,  C12N5/10 ,  C12N15/85 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

摘要： The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.

公开(公告)号：US20240100048A1

公开(公告)日：2024-03-28

申请号：US18532790

申请日：2023-12-07

申请人： INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： Rosa BARREIRA DA SILVA ,  Matthew ALBERT

IPC分类号： A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/001129 ,  A61K45/06 ,  A61P35/00 ,  A61K31/403

摘要： The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

公开(公告)号：US20240092858A1

公开(公告)日：2024-03-21

申请号：US18255951

申请日：2020-12-08

申请人： SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

发明人： Christina Zeitz ,  Deniz Dalkara ,  Juliette Varin ,  Isabelle Audo ,  Serge Picaud ,  José-Alain Sahel

IPC分类号： C07K14/705 ,  A61K48/00 ,  A61P27/02 ,  C12N15/86

CPC分类号： C07K14/70503 ,  A61K48/0058 ,  A61P27/02 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/008 ,  C12N2830/48

摘要： The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness

公开(公告)号：US20240012077A1

公开(公告)日：2024-01-11

申请号：US18474332

申请日：2023-09-26

申请人： Siemens Healthcare GmbH ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut National de La Sante et de la Recherche Medicale (INSERM) ,  King's College London ,  Department of Health and Human Services ,  UNIV PARIS XIII PARIS-NORD VILLETANEUSE ,  Universite de Paris

发明人： Giacomo Annio ,  Verena Müller-Reinwald ,  Ralph Sinkus ,  Omar Darwish ,  Wilfried Schnell ,  Tamara Elisabeth Falkner ,  Ahmed M. Gharib

IPC分类号： G01R33/48 ,  A61B5/055 ,  G01R33/563

CPC分类号： G01R33/48 ,  A61B5/055 ,  G01R33/56358 ,  A61B5/704

摘要： The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.

公开(公告)号：US20230263843A1

公开(公告)日：2023-08-24

申请号：US18300049

申请日：2023-04-13

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM ,  UNIVERSITE PARIS-SACLAY ,  Institut national de recherchepour l'agriculture, l'alimentation et l'environnement

发明人： Laurence ZITVOGEL ,  Bertrand ROUTY ,  Emmanuelle LE CHATELIER

IPC分类号： A61K35/744 ,  A61K39/395 ,  C12Q1/6886 ,  C12Q1/689

CPC分类号： A61K35/744 ,  A61K39/39558 ,  C12Q1/6886 ,  C12Q1/689 ,  A61K2039/55594

摘要： The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

公开(公告)号：US11713481B2

公开(公告)日：2023-08-01

申请号：US16753404

申请日：2018-10-05

申请人： Centre National de la Recherche Scientifique (CNRS) ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Sorbonne Universite

发明人： Marie-Charlotte Horny ,  Jean-Michel Siaugue ,  Vincent Dupuis ,  Mathieu Lazerges ,  Jean Gamby

IPC分类号： C12Q1/6834 ,  C12Q1/6825

CPC分类号： C12Q1/6834 ,  C12Q1/6825 ,  C12Q2523/305 ,  C12Q2527/107 ,  C12Q2563/116 ,  C12Q2563/143 ,  C12Q2563/155 ,  C12Q2565/607 ,  C12Q2565/629

摘要： A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.